Pipeline catalysts in 2H 2026 (SURF302 Aug, BEACH301 Q4) are key events. Near-term stock move hinges on clinical data, not financials. Monitor enrollment updates and early efficacy signals.
TYRA drugs
TYRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $36.19entry
- T+1 · 6mo ago +0.88%α +0.11% · $36.51
- T+5 · 6mo ago −6.66%α −5.50% · $33.78
- T+20 · 5mo ago −29.35%α −28.73% · $25.57
- T+60 · 3mo ago −26.75%α −31.19% · $26.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R&D spending. Cash and investments stood at $383.5M following a $147.9M ATM raise, extending runway into 2H 2028. Pipeline advancements include first patient dosed in potentially registrational SURF303 study and dose escalation cleared in BEACH301.
Key Financial Metrics
Key Facts
- Q1 2026 net loss per share -$0.64 vs -$0.47 in Q1 2025
- Cash and marketable securities of $383.5M; runway into 2H 2028
- Received $147.9M net proceeds from ATM offering (4,690,532 shares)
- First patient dosed in Phase 2a/b SURF303 study for LG-UTUC; initial results 2027
- SURF302 initial three-month complete response data expected August 2026 (n>20 enrolled)
- BEACH301 cleared fourth dose level; safety sentinel cohort results expected Q4 2026
Financial Impact
Net loss widened by 40% YoY; cash position strengthened by $147.9M ATM raise
Risk Factors
- Clinical trial failure or disappointing data in upcoming readouts
- Dilution from ATM offering (4.7M shares) may pressure stock
- Cash burn rate increasing with expanded clinical programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-220638 |
| Document: tyra-20260513.htm | 0001193125-26-220638 |
| Document: 0001193125-26-220638-index-headers.html | 0001193125-26-220638 |
| Document: 0001193125-26-220638-index.html | 0001193125-26-220638 |
| Document: 0001193125-26-220638.txt | 0001193125-26-220638 |
| 8-K Data (Synthetic) | 0001193125-26-220638 |
Track record
13 reports on TYRA
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Viewing Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers